6 completed, 5 terminated, 3 recruiting, 2 unknown. 17 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 6, Terminated 5, Recruiting 3, Unknown 2, Active not recruiting 1 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 1 | Completed 1 |
Follow ALL: new trials by email Literature Review of ALL trials Research Report on ALL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Study of CAR-T Cells in Primary Ph+All CD19 CAR-T cells - ALL | Phase 2 | Recruiting | Zhejiang University | 50 | 2025-11-30 | 2025-12-04 |
| Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL Inotuzumab Ozogamicin - ALL, MRD-positive | Phase 2 | Recruiting | Sheng-Li Xue, MD | 42 | 2022-08-01 | 2025-11-21 |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Clofarabine, Fludarabine, Busulfan - AML, ALL | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 31 | 2020-11-20 | 2026-03-13 |
| GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL Cohort 1, GNR-084, Cohort 2, GNR-084, Cohort 3, GNR-084 - B-precursor Acute Lymphoblastic Leukemia, ALL | Phase 1 / Phase 2 | Terminated | AO GENERIUM | 14 | 2020-10-15 | 2026-09-21 |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant Hyperbaric oxygen - AML, NHL | Phase 2 | Active not recruiting | University of Rochester | 64 | 2019-02-28 | 2026-07-20 |
| Haploidentical Donor vs mMUD in Hematological Malignancies Peripheral blood stem cells - AML, ALL | Phase 2 / Phase 3 | Completed | DKMS gemeinnützige GmbH | 98 | 2018-01-01 | 2024-08-07 |
| Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia Prednisone, Vincristine, Daunorubicin - ALL | Phase 2 | Unknown | PETHEMA Foundation | 30 | 2016-06-01 | 2022-02-18 |
| Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia OTS167IV - AML, Advanced MDS | Phase 1 / Phase 2 | Terminated | OncoTherapy Science, Inc. | 32 | 2016-04-01 | 2021-11-24 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancy, Leukemia | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 4 | 2012-03-01 | 2025-05-04 |
| Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Abatacept - AML, ALL | Phase 2 | Completed | Boston Children's Hospital | 11 | 2009-11-01 | 2019-11-21 |
| Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Clofarabine in combination with IV busulfan and ATG - MDS, AML | Phase 2 | Completed | Nantes University Hospital | 30 | 2009-10-01 | 2026-09-14 |
| Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) fludarabine phosphate, busulfan - AML, MDS | Phase 2 | Unknown | Samsung Medical Center | 114 | 2008-08-01 | 2008-12-30 |
| Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Naive T-cell Depleted Stem Cell Transplant, Stem Cell Transplant No Manipulation, Isolex device from Baxter - ALL, ANLL | Phase 1 / Phase 2 | Terminated | Duke University | 15 | 2007-07-01 | 2013-11-25 |
| Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD IL-2 - Acute Lymphoblastic Leukemia, ALL | Phase 2 | Completed | Baylor College of Medicine | 25 | 2007-06-01 | 2018-05-04 |
| Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Rapamycin, High dose etoposide and cytarabine (HiVAC) - ALL, Burkitt's Lymphoma | Phase 1 / Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 4 | 2007-01-01 | 2025-11-05 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF - AML, ALL | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 25 | 2002-12-01 | 2016-07-18 |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Cyclophosphamide, fludarabine, cyclosporine - AML, ALL | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 25 | 1999-07-01 | 2017-04-06 |
Hodgkin Disease (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia, Myeloid, Acute (4) · Lymphoma, Non-Hodgkin (4) · Myelodysplastic Syndromes (4) · Myeloproliferative Disorders (4) · Leukemia (3) · Anemia, Aplastic (2) · Hematologic Diseases (2) · Lymphoma (2) · Multiple Myeloma (2) · Neoplasms (2) · Anemia, Refractory (1) · Anemia, Refractory, with Excess of Blasts (1) · Blast Crisis (1)
Hemic and Lymphatic Diseases (11) · Neoplasms by Histologic Type (10) · Neoplasms (9) · Hematologic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Bone Marrow Diseases (6) · Leukemia (6) · Lymphoma (6) · Leukemia, Myeloid (5) · Pathological Conditions, Signs and Symptoms (5) · Anemia (4) · Leukemia, Lymphoid (4)
fludarabine (4) · Busulfan (3) · Cyclophosphamide (3) · fludarabine phosphate (3) · Clofarabine (2) · Cyclosporine (2) · Cytarabine (2) · Etoposide (2) · Methotrexate (2) · Mycophenolic Acid (2) · Abatacept (1) · Alemtuzumab (1) · Cyclosporins (1) · Daunorubicin (1) · Granulocyte Colony-Stimulating Factor (1)
Beth Israel Deaconess Medical Center (2) · AO GENERIUM (1) · Abramson Cancer Center at Penn Medicine (1) · Baylor College of Medicine (1) · Boston Children's Hospital (1) · DKMS gemeinnützige GmbH (1) · Duke University (1) · Memorial Sloan Kettering Cancer Center (1) · Nantes University Hospital (1) · OncoTherapy Science, Inc. (1) · PETHEMA Foundation (1) · Samsung Medical Center (1) · Sheng-Li Xue, MD (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Rochester (1)
United States (8) · China (2) · France (1) · Germany (1) · Russia (1) · South Korea (1) · Spain (1)
David E Avigan, MD (2) · David F McDermott, MD (2) · Dolores Grosso, DNP, CRNP (1) · Dong Hwan Kim (1) · Johannes Schetelig, Prof Dr med (1) · Leslie Kean, MD, PhD (1) · Maria Cancio, MD (1) · Mitchell Horwitz, MD (1) · Neal Flomenberg, MD (1) · Oksana A. Markova, MD (1) · Olatoyosi Odenike, MBBS (1) · Omar Aljitawi (1) · Rayne Rouce, MD (1) · Selina Luger, MD (1)
PMID 24047754, PMID 24573552, PMID 24951467, PMID 25852054, PMID 35622074, PMID 35675590, PMID 41671463
2015 (1)